Structure Therapeutics Inc. American Depositary Shares Cash Flow-to-Debt Ratio
Structure Therapeutics Inc. American Depositary Shares cash flow-to-debt ratio. Structure Therapeutics Inc. American Depositary Shares (GPCR) has a Cash Flow-to-Debt Ratio of -1.69x as of June 2026, meaning its operating cash flow of $-120.11 Million could theoretically repay -2% of its total liabilities ($71.01 Million) in one year. Check GPCR cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Structure Therapeutics Inc. American Depositary Shares (2020–2025)
Cash flow-to-debt ratio of Structure Therapeutics Inc. American Depositary Shares from 2020 to 2025. Historical debt coverage capacity for Structure Therapeutics Inc. American Depositary Shares across 6 annual periods. Check Structure Therapeutics Inc. American Dep investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Structure Therapeutics Inc. American Depositary Shares Cash Flow-to-Debt Ratio by Year (2020–2025)
Structure Therapeutics Inc. American Depositary Shares cash flow-to-debt ratio by year from 2020 to 2025. Year-by-year debt coverage analysis for Structure Therapeutics Inc. American Depositary Shares. For the full cash flow conversion analysis, see how efficiently does Structure Therapeutics Inc. American Dep generate cash.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.29x | $-222.20 Million | $67.54 Million | ▼ -8.6% |
| 2024 | -3.03x | $-116.64 Million | $38.49 Million | ▼ -10.8% |
| 2023 | -2.74x | $-79.49 Million | $29.05 Million | ▼ -1163.6% |
| 2022 | -0.22x | $-46.12 Million | $212.99 Million | ▼ -18.4% |
| 2021 | -0.18x | $-32.16 Million | $175.89 Million | ▲ +21.7% |
| 2020 | -0.23x | $-14.28 Million | $61.17 Million | — |